BioSpace News Archive

Bruker Corporation announced the launch of the FluoroType® SARS-CoV-2 plus next-generation 6-plex PCR assay for the highly specific detection of the SARS-CoV-2 virus, which causes the respiratory and systemic disease COVID-19.

Venatorx Pharmaceuticals announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services to advance a novel series of Penicillin Binding Protein Inhibitors targeting multi-drug resistant Acinetobacter baumannii through Phase 1 clinical testing.

Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time to discuss the financial results and recent business developments.

vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer’s Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional analyses of the clinical data from the STEADFAST Study of azeliragon showing the relative contribution of the effects on individual test items, as well as on the higher level cognitive and/or f

-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second Orphan Application DEER PARK, Ill., July 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. have mutually terminated the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi® (bremelanotide), a melanocortin receptor agonist indicated for th

Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma Over 50% of enrollment target achieved; full enrollment expected around year-end Potential for cosibelimab to be a best-in-class product with market disruptive pricing in a $25 billion PD-(L)1 class

Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs)

VitalHub Corp. is pleased to announce they have been selected by the National Health Service as one of two vendors to be included within the new NHS Framework Agreement.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce a five year white-label agreement with Fluum Inc. (“Fluum”), to launch a line of cannabis vape products designed to deliver enhanced experiences at a competitive price.